Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

    Research output: Contribution to journalLetterResearchpeer-review

  1. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Myelodysplastic syndrome patient-derived xenografts: from no options to many

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Deletions of chromosome 5q are associated with poor outcomes in acute myeloid leukemia (AML) suggesting the presence of tumor suppressor(s) at the locus. However, definitive identification of putative tumor suppressor genes remains controversial. Here we show that a 106-nucleotide noncoding RNA vault RNA2-1 (vtRNA2-1), previously misannotated as miR886, could potentially play a role in the biology and prognosis of AML. vtRNA2-1 is transcribed by polymerase III and is monoallelically methylated in 75% of healthy individuals whereas the remaining 25% of the population have biallelic hypomethylation. AML patients without methylation of VTRNA2-1 have a considerably better outcome than those with monoallelic or biallelic methylation (n = 101, P = .001). We show that methylation is inversely correlated with vtRNA2-1 expression, and that 5-azanucleosides induce vtRNA2-1 and down-regulate the phosphorylated RNA-dependent protein kinase (pPKR), whose activity has been shown to be modulated by vtRNA2-1. Because pPKR promotes cell survival in AML, the data are consistent with vtRNA2-1 being a tumor suppressor in AML. This is the first study to show that vtRNA2-1 might play a significant role in AML, that it is either mono- or biallelically expressed in the blood cells of healthy individuals, and that its methylation state predicts outcome in AML.
Original languageEnglish
JournalBlood
Volume119
Issue number1
Pages (from-to)206-16
Number of pages11
ISSN0006-4971
DOIs
Publication statusPublished - 2012

ID: 33232004